- Home
- CCCC
CCCC
C4 Therapeutics Inc.
as 05-13-2025 4:00pm EST
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 115.0M | IPO Year: | 2020 |
| Target Price: | $12.50 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.08 - $7.66 | Next Earning Date: | 05-07-2025 |
| Revenue: | $39,783,000 | Revenue Growth: | 98.56% |
| Revenue Growth (this year): | -30.69% | Revenue Growth (next year): | 36.31% |
Stock Insider Trading Activity of C4 Therapeutics Inc. (CCCC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Boyle Scott N | CCCC | Chief Business Officer | Feb 13 '25 | Sell | $3.15 | 1,159 | $3,650.85 | 110,842 |
Latest C4 Therapeutics Inc. News
CCCC Breaking Stock News: Dive into CCCC Ticker-Specific Updates for Smart Investing
Zacks
6 days ago
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
6 days ago
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Simply Wall St.
21 days ago
April 2025's Standout Penny Stocks
Zacks
2 months ago
C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
MT Newswires
2 months ago
UBS Adjusts C4 Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating
Simply Wall St.
3 months ago
C4 Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
Zacks
3 months ago
C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks
3 months ago
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates
Compare CCCC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CCCC C4 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.